Augustine Therapeutics
Manufacturing · Belgium · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Gaston Geenslaan 3, Leuven, Flanders, 30...Website
www.augustinetx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Augustine Therapeutics
Augustine Therapeutics specializes in developing selective and safe HDAC6 inhibitors aimed at treating neuromuscular, neurodegenerative, and cardiometabolic diseases. Their innovative approach addresses the limitations of previous HDAC6 inhibitors by utilizing a novel non-hydroxamate, non-hydrazine chemotype that enhances specificity and reduces toxicity. The company is advancing a diverse pipeline, including their lead program AGT-100XXX, which is in IND-enabling studies for various indications. With a leadership team experienced in drug development, Augustine Therapeutics is positioned to make a significant impact in chronic disease treatment.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Augustine Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Augustine Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Augustine Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Augustine Therapeutics is spiking on competitors!
Check if Augustine Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Augustine Therapeutics
Product Launch: Get notified when Augustine Therapeutics launches new products
Click to see if Augustine Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Augustine Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Augustine Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Augustine Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Augustine Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Augustine Therapeutics.
Augustine Therapeutics financials insights
Gather financial insights about Augustine Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$85M
Augustine Therapeutics Tech Stack
A closer look at the technologies used by Augustine Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
Funding
Funding
Augustine Therapeutics News & Media
Belgium's 10 biggest funding rounds in H1 2025; 5 are hiring - Silicon Canals
In this article, we have highlighted the 10 biggest funding rounds in Belgium from the first half of 2025.Augustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease
LEUVEN, Belgium – 27 May 2025– Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology company focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, today announces it has dosed the first patient in its Phase I clinical trial evaluating lead candidate AGT-100216, the first peripherally-restricted, selective HDAC6 inhibitor (HDAC6i) for the treatment ofAugustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary
Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiaryAugustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO
Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Augustine Therapeutics
Sign Up For FreeTo access detailed company insights
Augustine Therapeutics specializes in developing selective and safe HDAC6 inhibitors aimed at treating neuromuscular, neurodegenerative, and cardiometabolic diseases. Their innovative approach addresses the limitations of previous HDAC6 inhibitors by utilizing a novel non-hydroxamate, non-hydrazine chemotype that enhances specificity and reduces to... Read More
